| Ytd | -47.64% | |
| 1y | -41.06% |
| Open | 1.20 | Prev Close | 1.20 | Low | 1.20 | High | 1.23 | Mkt Cap | 71.05M |
| Vol | 338.47K | Avg Vol | 1.53M | EPS | 0.14 | P/E | 8.71 | Forward P/E | -0.83 |
| Beta | 0.63 | Short Ratio | 2.08 | Inst. Own | 23.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.56 | 200-d Avg | 2.25 | 1yr Est | 5.00 |
SPRO News
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward i
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clini
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated dise
Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-license
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater Chin
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therap
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Comp
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today a
FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK
https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analy
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), includ
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clini
Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Fr
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.53 per share which beat the analy
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clin
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the com
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte